With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space
Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.